Combined Therapy With Surgery and Anti-TNF Therapy for Perianal Crohnʼs Disease: Seton Withdrawal Timing Data From a Brazilian Case Series

2012 ◽  
Vol 18 ◽  
pp. S59
Author(s):  
Paulo Kotze ◽  
Idblan Albuquerque ◽  
Andre Moreira ◽  
Claudio Coy ◽  
Ana Pugas de Carvalho ◽  
...  
Keyword(s):  
Combined Therapy ◽  
Case Series ◽  
Timing Data ◽  
Brazilian Case

scholarly journals Cryptococcosis in non-HIV/non-transplant patients: A Brazilian case series

2016 ◽  
Vol 54 (7) ◽  
pp. 669-676 ◽  
Author(s):  
Naiane Ribeiro Lomes ◽  
Marcia Souza de Carvalho Melhem ◽  
Maria Walderez Szeszs ◽  
Marilena dos Anjos Martins ◽  
Renata Buccheri
Keyword(s):  
Case Series ◽  
Transplant Patients ◽  
Brazilian Case

scholarly journals Combination therapy of omalizumab with house dust mite immunotherapy in chronic spontaneous urticaria associated with sensitization to dust mites-case series

2021 ◽  
pp. 469-472
Author(s):  
P C Kathuria ◽  
Manisha Rai
Keyword(s):  
Combination Therapy ◽  
Disease Control ◽  
House Dust ◽  
House Dust Mite ◽  
Immunoglobulin E ◽  
Combined Therapy ◽  
Case Series ◽  
Chronic Spontaneous Urticaria ◽  
Dust Mite ◽  
Urticaria Activity Score

Chronic spontaneous urticaria (CSU) is a heterogeneous disorder with recurrent pruritic wheals and/or angioedema. The anti-immunoglobulin E (omalizumab) is used in CSU patients resistant to four-fold second-generation anti-histamines. Most clinical trials have experienced relapse after stopping omalizumab treatment. Here, we present a case series of five cases of chronic atopic urticarial concomitant allergic rhinitis and asthma which have shown immunologically significant positivity to Dermatophagoides pteronyssinus and Dermatophagoides farinae. Disease control was achieved (Urticaria Activity Score 7 <6) in four cases by combination therapy of omalizumab with house dust mite (HDM) Allergen Immunotherapy (AIT) and remained sustained for three years on follow-up even after discontinuation of AIT for one year. We hypothesize that this combined therapy may contribute to enhanced clinical efficacy, safety, and faster achievement of disease control in CSU.

scholarly journals Severe cutaneous adverse drug reactions: diagnostic approach and genetic study in a Brazilian case series

2021 ◽  
Author(s):  
M. I. Perello ◽  
A. de Maria Castro ◽  
A. C. Nogueira Arraes ◽  
S. Caracciolo Costa ◽  
D. Lacerda Pedrazzi ◽  
...  
Keyword(s):  
Adverse Drug Reactions ◽  
Genetic Study ◽  
Case Series ◽  
Diagnostic Approach ◽  
Drug Reactions ◽  
Brazilian Case

scholarly journals Differential Effects of an Evolutionary-Based EMDR Therapy on Depression and Anxiety Symptoms: A Case Series Study

2018 ◽  
Vol 12 (2) ◽  
pp. 46-57 ◽  
Author(s):  
Valery Krupnik
Keyword(s):  
Depressive Disorders ◽  
Combined Therapy ◽  
Case Series ◽  
Anxiety Symptoms ◽  
Future Research ◽  
Depression And Anxiety ◽  
Case Series Study ◽  
Acceptance And Action Questionnaire ◽  
Series Study ◽  
Emdr Therapy

A novel evolutionary-based therapy, treating depression downhill (TDD), was designed as a specific therapy for depression as a syndrome (Krupnik, 2014) and later integrated with eye movement desensitization and reprocessing (EMDR) therapy into a combined TDD-EMDR treatment. The combined therapy integrates modified EMDR procedures into the theoretical context of TDD. These procedures are applied during the second (acceptance) stage of TDD-EMDR’s three-stage proltocol with the focus on acceptance of defeat/failure/loss rather than on distressing memories. Here, we report a case series of 21 military personnel diagnosed with depressive disorders, who received a course of TDD-EMDR. Eighty percent of completers (n = 15) did not meet the criteria of depressive disorder by the treatment’s end. After 12 sessions, they showed a significant reduction on the Beck’s Depression Inventory-II (BDI-II) with a large effect size (d = 2.8) and an increase in accepting disposition (d = 1.8) on the Acceptance and Action Questionnaire. Noncompleters showed similar to completers decrease of BDI-II scores at mid-treatment. We observed no statistically significant decrease of the anxiety symptoms on the Beck’s Anxiety Inventory. These results suggest that TDD-EMDR may be an effective treatment for depressive disorders. They also indicate that it may preferentially target depressive over anxiety symptoms, as was previously observed for TDD. Suggestions are made for future research.

Cariprazine

2020 ◽  
Vol 39 (04) ◽  
pp. 238-241 ◽  
Author(s):  
Maximilian Gahr ◽  
Simon Riedesser
Keyword(s):  
Clinical Studies ◽  
Negative Symptoms ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Case Series ◽  
Serum Levels ◽  
Treatment Setting ◽  
Serum Prolactin ◽  
Therapeutic Effects ◽  
Treatment Settings

Abstract Objective Cariprazine is a new antipsychotic drug approved for the treatment of schizophrenia in Europe in 2017. Clinical studies suggest advantages of cariprazine in comparison to other antipsychotic agents regarding therapeutic effects on “negative symptoms”, antipsychotic-induced weight gain and increased serum prolactin levels. Akathisia was reported to be one of the most common side effects. Currently, however, data from naturalistic treatment settings regarding the efficacy, safety and tolerability of cariprazine are missing. Thus, we report and discuss our clinical experiences with cariprazine regarding efficacy, safety and tolerability in order to provide first treatment data from a naturalistic treatment setting. Material and methods The course of treatment of a series of 3 patients with schizophrenia spectrum disorders and treatment with cariprazine (mono- or combined therapy) is presented and discussed. Results Cariprazine demonstrated sufficient antipsychotic effects in 2 out of 3 cases; however, in 2 out of 3 cases treatment had to be discontinued due to akathisia/agitation; in 1 case, cariprazine monotherapy facilitated successful normalization of elevated prolactin serum levels (due to combined treatment with risperidone and olanzapine). Conclusion(s): In general, experience with cariprazine within a naturalistic treatment setting is in accordance with data from clinical studies, particularly concerning effects on “negative symptoms”, antipsychotic-associated elevation of prolactin serum levels and risk of akathisia. The comparatively high incidence of discontinuation of cariprazine due to akathisia/agitation in our case series may be an effect of polypharmacy which was very common among our three cases. Clinical relevance This case series provides some evidence that safety, tolerability and antipsychotic efficacy of cariprazine in naturalistic treatment settings may be similar to findings from the available clinical studies.

scholarly journals P14.61 Tumor Treating Fields (TTFields) combined with lomustine (CCNU) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) patients - a bi-centric analysis

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii81-iii81
Author(s):  
L Lazaridis ◽  
N Schäfer ◽  
T Schmidt ◽  
A Stoppek ◽  
J Weller ◽  
...  
Keyword(s):  
Combined Therapy ◽  
Performance Status ◽  
Methylation Status ◽  
Case Series ◽  
Low Grade ◽  
Newly Diagnosed ◽  
Skin Reactions ◽  
Term Survival ◽  
Tumor Treating Fields ◽  
Newly Diagnosed Glioblastoma

Abstract BACKGROUND TTFields combined with TMZ demonstrated significantly improved PFS, OS and long-term survival in newly diagnosed glioblastoma (ndGBM) patients, compared to TMZ monotherapy in the EF-14 trial; independent of MGMT-promotor methylation-status, age, grade of resection and performance status. Recently, improved efficacy of lomustine (CCNU)/TMZ compared to TMZ monotherapy in ndGBM patients with MGMT-promotor methylation was reported in the CeTeG trial (NOA-09). Taken into account that TTFields showed a strong safety profile as well as a high potential being combined with other modalities and the very encouraging results for methylated MGMT-promotor GBM patients in the CeTeG trial, there is a strong rationale in combining these treatment regimens. Here, we present a case series of patients receiving a combination of both modalities, TTFields and CCNU/TMZ. METHODS Patients with ndGBM and MGMT-promotor methylation underwent a combined therapy of TTFields plus CCNU/TMZ after surgery and radiochemotherapy. Safety, feasibility as well as first efficacy results of this combined therapy are reported at data cut-off (31.12.2018). Most recent data, including compliance to TTFields therapy, will be presented at the EANO annual meeting. RESULTS Twelve patients with MGMT-promotor methylated ndGBM (median, range: age 49.5, 26–69; KPS 90, 60–100) have been treated with a combination of TTFields plus CCNU/TMZ. The analysis included patients with complete resection (n=6), partial resection (n=5) as well as biopsy (n=1). CTCAE grade 3 hematotoxicities were observed in six patients, but were not considered to be related to the addition of TTFields to lomustine/TMZ. Medical device site reactions (low-grade skin reactions) were detected in five patients. At data cut-off, the analyzed patient population demonstrated a median PFS of 18.7 months, whereas the median OS was not yet reached. CONCLUSION The results of this analysis provide first indication that the combination of TTFields/lomustine/TMZ is safe and feasible. Moreover, the observed survival outcomes point to preliminary beneficial effects of the triple combination. Additional follow-up and a higher sample size is required and planned for further toxicity analysis and efficacy assessment of this combination.

Brachioradial pruritus - descriptive analysis of Brazilian case series

2013 ◽  
Vol 11 (6) ◽  
pp. 530-535 ◽  
Author(s):  
Paula Y. Masuda ◽  
Antonio Carlos Ceribelli Martelli ◽  
Patrick A. Wachholz ◽  
Hélcio T. Akumatsu ◽  
Ana L. G. P. Martins ◽  
...  
Keyword(s):  
Descriptive Analysis ◽  
Case Series ◽  
Brazilian Case

scholarly journals Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine

2021 ◽  
Vol 12 ◽  
Author(s):  
Marcello Silvestro ◽  
Alessandro Tessitore ◽  
Fabrizio Scotto di Clemente ◽  
Giorgia Battista ◽  
Gioacchino Tedeschi ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Therapeutic Strategy ◽  
Combined Therapy ◽  
Case Series ◽  
Additive Interaction ◽  
C Fibers ◽  
Onabotulinumtoxin A ◽  
Effective Therapeutic Strategy ◽  
Refractory Migraine ◽  
European Headache Federation

In the last decade, notable progresses have been observed in chronic migraine preventive treatments. According to the European Headache Federation and national provisions, onabotulinumtoxin-A (BTX-A) and monoclonal antibodies acting on the pathway of calcitonin gene–related peptide (CGRP-mAbs) should not be administered in combination due to supposed superimposable mechanism of action and high costs. On the other hand, preclinical observations demonstrated that these therapeutic classes, although operating directly or indirectly on the CGRP pathway, act on different fibers. Specifically, the CGRP-mAbs prevent the activation of the Aδ-fibers, whereas BTX-A acts on C-fibers. Therefore, it can be argued that a combined therapy may provide an additive or synergistic effect on the trigeminal nociceptive pathway. In the present study, we report a case series of 10 patients with chronic migraine who experienced significant benefits with the combination of both erenumab and BTX-A compared to each therapeutic strategy alone. A reduction in frequency and intensity of headache attacks (although not statistically significant probably due to the low sample size) was observed in migraine patients treated with a combined therapy with BTX-A and erenumab compared to both BTX-A and erenumab alone. Moreover, the combined therapy with BTX-A and erenumab resulted in a statistically significant reduction in the symptomatic drug intake and in migraine-related disability probably related to a reduced necessity or also to a better responsiveness to rescue treatments. Present data suggest a remodulation of current provisions depriving patients of an effective therapeutic strategy in peculiar migraine endophenotypes.

scholarly journals Early hydroxychloroquine and azithromycin as combined therapy for COVID-19: a case series

2020 ◽  
Vol 52 (03) ◽  
Author(s):  
Siswanto Siswanto ◽  
Oktaviarum S. Utama ◽  
Agit S. Adisetiadi ◽  
Maria E. Pranasakti ◽  
Mohamad S. Hakim
Keyword(s):  
Combined Therapy ◽  
Case Series

scholarly journals Liver Damage in Pediatric Critically Ill COVID-19 Patients: Brazilian Case-Series

2020 ◽  
pp. 1-6
Author(s):  
Michele Luglio ◽  
Uenis Tannuri ◽  
Werther Brunow de Carvalho ◽  
Maria Fernanda Badue Pereira ◽  
Isadora Souza Rodrigues ◽  
...  
Keyword(s):  
Critical Care ◽  
Inflammatory Response ◽  
Critically Ill ◽  
Liver Damage ◽  
Pediatric Patients ◽  
Case Series ◽  
Critical Care Admission ◽  
Inflammatory Syndrome ◽  
Brazilian Case

Coronavirus disease 2019 (COVID-19) has become an important cause critical care admission worldwide. In the context of newly described multisystem inflammatory syndrome temporally related to SARS-CoV-2 (PIM-TS), the question of liver compromise came into evidence. Our group summarized a case series of 6 critically ill COVID-19 pediatric patients that presented some degree of liver damage, as demonstrated by liver and/or canalicular enzymes elevation, a yet not fully explored characteristic of the infection in the pediatric patient, that may indicate a more severe progression. Observations regarding the role of systemic inflammatory response can be taken from the described cases.

Sign in / Sign up

Export Citation Format

Share Document